医学
造血干细胞移植
耐火材料(行星科学)
挽救疗法
细胞因子释放综合征
微小残留病
内科学
移植
嵌合抗原受体
白血病
干细胞
胃肠病学
肿瘤科
免疫学
T细胞
化疗
免疫系统
生物
天体生物学
遗传学
作者
Jingsheng Hua,Jian Zhang,Xiaoxia Wu,Lili Zhou,Xiebing Bao,Yue Han,Miao Miao,Caixia Li,Zhengzheng Fu,Depei Wu,Weiqing Qian,Huiying Qiu
标识
DOI:10.1016/j.clml.2020.04.007
摘要
Introduction Currently, effective and safe salvage therapies are limited among patients with relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Anti-CD19 chimeric antigen receptor T (CAR T) cell is a promising treatment. Patients and Methods We studied 11 patients with B-cell acute lymphoblastic leukemia that relapsed after allo-HSCT between September 2017 and October 2019. Patients were treated with a dose of single-infusion donor-derived anti-CD19 CAR T cells. Results Eight patients (72.7%) experienced morphologic remissions. Seven (63.6%) experienced minimal residual disease–negative remission. The ongoing complete remission (CR) duration of 2 patients reached 22 months. The median overall survival was 9 months (range, 2-22 months). Only one patient with grade 1 acute graft-versus-host disease was observed. Two patients (18.2%) developed grade 3/4 cytokine release syndrome. Conclusion This prospective study showed allogeneic donor-derived anti-CD19 CAR T-cell therapy is an effective and safe salvage regimen for patients with relapsed/refractory B-cell acute lymphoblastic leukemia after allo-HSCT. Further randomized and multicenter investigations are needed to evaluate their potential role in relapsed acute lymphoblastic leukemia therapies after allo-HSCT.
科研通智能强力驱动
Strongly Powered by AbleSci AI